| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/15/2001 | CA2348067A1 Composition for extending post meal satiety |
| 03/15/2001 | CA2286408A1 The use of msm |
| 03/14/2001 | EP1083230A1 Viral replicons and viruses dependent on inducing agents |
| 03/14/2001 | EP1083196A1 Underwater granulation of therapeutic agent containing melts |
| 03/14/2001 | EP1083184A2 Silicon-containing polymers, their preparation and their use |
| 03/14/2001 | EP1082963A1 Remedies for joint diseases bound to hyaluronic acid |
| 03/14/2001 | EP1082911A2 Food using gamma-aminobutyric acid-enriched cruciferous plant |
| 03/14/2001 | EP1082289A1 Methods for identifying novel multimeric agents that modulate receptors |
| 03/14/2001 | EP1082142A2 Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |
| 03/14/2001 | EP1082139A2 CARRIER FOR $i(IN VIVO) DELIVERY OF A THERAPEUTIC AGENT |
| 03/14/2001 | EP1082138A1 Texaphyrin conjugates and uses thereof |
| 03/14/2001 | EP1082135A1 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| 03/14/2001 | EP1082133A2 Pharmaceutical formulations for igf/igfbp |
| 03/14/2001 | EP1082123A1 Use of a nucleic acid-binding chemotherapeutic agent, and a pharmaceutical composition |
| 03/14/2001 | EP1082119A1 Microemulsion preconcentrates containing a piperidine substance p antagonist |
| 03/14/2001 | EP1082117A1 A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer |
| 03/14/2001 | EP1082109A1 Oral formulation comprising biguanide and an organic acid |
| 03/14/2001 | EP1082107A1 Controlled release lipoic acid |
| 03/14/2001 | EP1082105A1 Controlled drug delivery system using the conjugation of drug to biodegradable polyester |
| 03/14/2001 | EP1082104A1 Novel poly(methylidene malonate) microspheres, preparation method and pharmaceutical compositions containing them |
| 03/14/2001 | EP1082103A1 Spill resistant pharmaceutical compositions |
| 03/14/2001 | EP1082102A1 Biologically active composition |
| 03/14/2001 | EP1082029A1 Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 03/14/2001 | EP0831817B1 Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent |
| 03/14/2001 | EP0804601B1 Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle |
| 03/14/2001 | EP0584279B1 Targeted delivery of genes encoding immunogenic proteins |
| 03/14/2001 | CN1287495A Powdery pernasal compositions |
| 03/13/2001 | US6201164 Hydrocolloid wound gel |
| 03/13/2001 | US6201110 Mixture of protease conjugated to polymer with molecular weight from 1 to 60 kilodaltons and another substance which makes it unsuitable for pharmaceutical use; cosmetics; dentrifices; detergents; hair spray; shampoo; agrochemicals |
| 03/13/2001 | US6201072 Block copolymers of polyether and polyester |
| 03/13/2001 | US6201065 Multiblock biodegradable hydrogels for drug delivery and tissue treatment |
| 03/13/2001 | US6201020 Effective poly(adenosine 5'-diphospho-ribose) polymerase (parp) inhibitor for treatment of tissue damage by necrosis or apoptosis; side effect reduction |
| 03/13/2001 | US6201009 Absorption-enhancing composition for pantothenic acid derivative |
| 03/13/2001 | US6200983 For treating erectile dysfunction in psychogenic male patients; time-release agents |
| 03/13/2001 | US6200968 Particle-forming compositions containing fused pyrrolocarbazoles |
| 03/13/2001 | US6200964 Silicone gel containing salicylic acid |
| 03/13/2001 | US6200956 Nucleic acid-containing composition, preparation and use thereof |
| 03/13/2001 | US6200801 A polycation and a binding moiety of defined amino acid sequence capable of binding to a serpin enzyme complex receptor for targeted gene delivery; gene therapy; antisense agents |
| 03/13/2001 | US6200606 Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
| 03/13/2001 | US6200603 Comestible capsules having flavored coatings |
| 03/13/2001 | US6200602 Mixture of polar drug and absorption promoter |
| 03/13/2001 | US6200599 Ortho ester lipids |
| 03/13/2001 | US6200598 Active materials entrapped within liposome interior |
| 03/13/2001 | US6200594 Breast-enhancing, herbal compositions and methods of using same |
| 03/13/2001 | US6200566 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| 03/13/2001 | US6200558 Peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing n2o2-functional group |
| 03/13/2001 | US6200557 Activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate |
| 03/13/2001 | US6200548 Gas or air filled polymeric microballoons |
| 03/13/2001 | CA2170647C Multiple unit tableted dosage form i |
| 03/13/2001 | CA2135132C Lysine derivatives with an n6-alkoxy or alkenoxycarbonyl group, their preparation and use in cosmetic, pharmaceutical, hygyenic or dietetic compositions |
| 03/08/2001 | WO2001016306A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 03/08/2001 | WO2001016290A2 Dna encoding the human serine protease eos |
| 03/08/2001 | WO2001016289A2 Zymogen activation system |
| 03/08/2001 | WO2001016218A1 Rapidly decomposing chitosan-based pellets |
| 03/08/2001 | WO2001016169A2 RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE |
| 03/08/2001 | WO2001016137A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 03/08/2001 | WO2001016106A1 Benzamide formulation with histone deacetylase inhibitor activity |
| 03/08/2001 | WO2001015755A2 Methods and compositions for delivery of pharmaceutical agents |
| 03/08/2001 | WO2001015746A1 Radiopharmaceutical products and their preparation procedure |
| 03/08/2001 | WO2001015745A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | WO2001015738A2 Nitric oxide-producing hydrogel materials |
| 03/08/2001 | WO2001015737A2 Method for coupling molecules |
| 03/08/2001 | WO2001015734A2 High viscosity liquid controlled delivery system and medical or surgical device |
| 03/08/2001 | WO2001015726A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | WO2001015718A1 Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof |
| 03/08/2001 | WO2001015699A1 Injectable buprenorphine microparticle compositions and their use |
| 03/08/2001 | WO2001015694A1 Extended duration light activated cancer therapy |
| 03/08/2001 | WO2001015691A1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 03/08/2001 | WO2001015688A1 Ibuprofen-containing softgels |
| 03/08/2001 | WO2001015683A1 Delayed-action form of administration containing tramadol saccharinate |
| 03/08/2001 | WO2001015682A1 Pharmaceutical tramadol salts |
| 03/08/2001 | WO2001015681A1 Oral pharmaceutical forms of administration with a delayed action |
| 03/08/2001 | WO2001015671A2 Flushable disposable polymeric products |
| 03/08/2001 | WO2001015670A1 Treatment of fungal infections utilizing a fungal growth medium |
| 03/08/2001 | WO2001015669A1 Pharmaceutical preparation containing nanosol |
| 03/08/2001 | WO2001015668A1 Controlled release pellet formulation |
| 03/08/2001 | WO2001015667A1 Oral dosage forms |
| 03/08/2001 | WO2001015666A1 Mixed micellar pharmaceutical delivery system and method of preparation |
| 03/08/2001 | WO2001015665A1 Controlled release oral dosage suitable for oral administration |
| 03/08/2001 | WO2001015664A2 Coformulation methods and their products |
| 03/08/2001 | WO2001015511A2 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| 03/08/2001 | WO2000061192A3 Methods and compositions for the treatment of pancreatitis |
| 03/08/2001 | WO2000057870A3 Viral treatment |
| 03/08/2001 | WO2000054762A3 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 03/08/2001 | WO2000041546A9 Novel exendin agonist formulations and methods of administration thereof |
| 03/08/2001 | WO2000039290A3 Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid |
| 03/08/2001 | WO2000006243A3 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 03/08/2001 | WO1999064047A8 Novel antiviral compounds |
| 03/08/2001 | WO1999063930A8 Novel angiotensin receptor modulators and their uses |
| 03/08/2001 | DE19944547C1 Surfactant mixture of alkyloligoglycosides and betaine, useful in cosmetic, pharmaceutical and cleaning compositions, is almost odorless |
| 03/08/2001 | DE19941769A1 Cosmetic or dermatological active agent combination of cyclodextrin and biotin compound, useful in care or protection of skin, e.g. for treatment or prevention of aging symptoms or photodermatosis |
| 03/08/2001 | DE19940227A1 Phospholipidgel Phospholipid |
| 03/08/2001 | CA2391844A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | CA2388560A1 Sustained-release form of administration containing tramadol saccharinate |
| 03/08/2001 | CA2383601A1 Dna encoding the human serine protease eos |
| 03/08/2001 | CA2383517A1 Radiopharmaceutical products and their preparation procedure |
| 03/08/2001 | CA2382961A1 Zymogen activation system |
| 03/08/2001 | CA2382611A1 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | CA2382556A1 Coformulation methods and their products |
| 03/08/2001 | CA2382499A1 Method for coupling molecules |